MetabolicIn Clinical Trials

Pemvidutide

Subcutaneous injection

Overview

Pemvidutide is a dual receptor agonist targeting both glucagon-like peptide-1 (GLP-1) and glucagon receptors, designed to combine the insulinotropic and appetite-suppressing effects of GLP-1 with the energy expenditure and lipolytic actions of glucagon. This balanced co-agonist strategy aims to achieve superior weight loss and metabolic benefits compared to GLP-1 monotherapy while mitigating the hyperglycemic effects of isolated glucagon receptor activation.

Mechanism of Action

The peptide architecture incorporates amino acid modifications to optimize receptor binding affinity and pharmacokinetic duration..

Research Summary & Key Findings

Phase 2 trial data presented at major endocrinology conferences in 2023 and 2024 reported substantial weight reductions exceeding 10 percent at 16 weeks in patients with obesity, along with improvements in lipid profiles and liver fat content. The compound is advancing through mid-stage development with ongoing trials in both obesity and metabolic dysfunction-associated steatohepatitis, though peer-reviewed publications are still emerging.

Clinical Status

In Clinical Trials

Pemvidutide is currently undergoing clinical trials. It is not yet FDA-approved and is available only through clinical research settings or investigational protocols.

Administration Routes

Subcutaneous injection

Related Peptides in Metabolic

Semaglutide (Ozempic/Wegovy)

FDA Approved

A glucagon-like peptide-1 receptor agonist (GLP-1 RA) with 94% amino acid homology to native GLP-1. Semaglutide enhances...

View details

Tirzepatide (Mounjaro/Zepbound)

FDA Approved

A first-in-class dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor agonist. Tirzepatide activat...

View details

Retatrutide

In Clinical Trials

An investigational triple hormone receptor agonist targeting GLP-1, GIP, and glucagon receptors simultaneously. The gluc...

View details

AOD-9604

Investigational

A modified 16-amino acid fragment (amino acids 176-191) of the C-terminus of human growth hormone with an added tyrosine...

View details

Find a Provider

Find a verified provider who offers Pemvidutide therapy in your area.

Browse Provider Map

Find a Pharmacy

Browse PCAB-accredited and FDA 503B-registered compounding pharmacies that supply Pemvidutide.

Pharmacy Directory

Join the Association

Access exclusive peptide protocols, provider resources, and community support.

List Your Practice

Disclaimer: This information is provided for educational and research purposes only. It is not intended as medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting any peptide therapy. The Peptide Association does not endorse or recommend any specific treatment protocol.